Brokers Offer Predictions for Nanobiotix FY2026 Earnings

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) – Analysts at HC Wainwright dropped their FY2026 earnings estimates for Nanobiotix in a report issued on Monday, May 18th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings of $0.37 per share for the year, down from their previous forecast of $1.41. HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Nanobiotix’s current full-year earnings is $0.53 per share. HC Wainwright also issued estimates for Nanobiotix’s FY2027 earnings at $0.84 EPS, FY2028 earnings at $0.66 EPS and FY2029 earnings at $1.87 EPS.

Nanobiotix (NASDAQ:NBTX) last released its earnings results on Sunday, February 15th. The company reported ($0.23) earnings per share (EPS) for the quarter. The company had revenue of $3.42 million for the quarter.

Several other equities analysts have also weighed in on NBTX. Guggenheim upped their price objective on shares of Nanobiotix from $26.00 to $36.00 and gave the company a “buy” rating in a report on Thursday, April 2nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Nanobiotix in a report on Tuesday, April 21st. TD Cowen reiterated a “buy” rating on shares of Nanobiotix in a report on Thursday, March 12th. Finally, UBS Group upped their price objective on shares of Nanobiotix from $3.50 to $30.00 and gave the company a “neutral” rating in a report on Friday, May 1st. Four research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $26.67.

Nanobiotix Stock Performance

NBTX stock opened at $46.20 on Wednesday. Nanobiotix has a 12-month low of $3.64 and a 12-month high of $57.14. The company’s fifty day simple moving average is $35.60 and its 200 day simple moving average is $27.24.

Institutional Investors Weigh In On Nanobiotix

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Royal Bank of Canada raised its holdings in shares of Nanobiotix by 2,000.0% in the 4th quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock worth $61,000 after acquiring an additional 2,500 shares during the last quarter. Optiver Holding B.V. acquired a new stake in shares of Nanobiotix in the 3rd quarter worth about $101,000. Marshall Wace LLP acquired a new stake in shares of Nanobiotix in the 4th quarter worth about $220,000. Finally, Millennium Management LLC acquired a new stake in shares of Nanobiotix in the 4th quarter worth about $390,000. Institutional investors and hedge funds own 38.81% of the company’s stock.

About Nanobiotix

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.